Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7852W HIGH $6.50
Volume
15.86 K
Value Traded
730.82 K
Short % Float
5.73%
-3.7%Week
+5.14%1 Month
+43.61%3 Month
+38.74%6 Month
-60%5 Year
-64.42%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
341.10 M
EPS (TTM)
-0.98
P/E Ratio
-
Ent. Value
249.14 M
Total Shares
60.11 M
Float Shares
41.39 M
Insiders
31.14%
Institutions
46.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
OBIO Catalyst Timeline
Dated clinical, regulatory and corporate events for Orchestra BioMed Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Orchestra BioMed Holdings, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How OBIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Orchestra BioMed Holdings, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every OBIO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sherman DarrenDirector, Officer (See Remarks) | Sell | -15,000 1,119,402 held | $6.36 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OBIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.4 % | 41.23 M | 9.56 M | 15.05% ( 1.25 M) |
OBIO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OBIO ranks across every disease it competes in
Competitive Position is a premium feature
See how OBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOBIO News
OBIOOrchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
Orchestra BioMed has exceeded its enrollment target in the BACKBEAT Trial, enrolling 330 patients for the evaluation of AVIM Therapy in managing uncontrolled hypertension. The trial aims to provide data supporting future marketing applications to the FDA and other regulatory bodies. Results are expected to be presented at a major cardiovascular conference in Q2 2027.
Read more →OBIOOrchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Orchestra BioMed announced that its investigational AVIM Therapy will be featured in two sessions at HRX Live 2026. The sessions will focus on its collaboration with Medtronic to develop AVIM Therapy for uncontrolled hypertension. Clinical evidence suggests AVIM Therapy can significantly reduce blood pressure in patients indicated for cardiac pacemakers. The BACKBEAT Trial is nearing completion, showcasing the therapy's potential impact.
Read more →OBIOOrchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Orchestra BioMed has received a $6.1 million milestone payment following the acquisition of Vivasure Medical by Haemonetics. This payment adds to the $5 million received earlier in the year, totaling approximately $11 million. The company is also eligible for up to $10 million in additional proceeds based on future revenue milestones, enhancing its capital for pivotal programs.
Read more →OBIOOrchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Orchestra BioMed has announced the granting of stock options to seven new employees under its 2025 New Hire Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The company focuses on high-impact biomedical technologies, with its lead products, AVIM Therapy and Virtue SAB, currently in pivotal clinical trials and addressing significant market needs.
Read more →OBIOOrchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Orchestra BioMed Holdings, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. CEO David Hochman will lead the presentation and host one-on-one meetings with investors. The company is known for its innovative therapies, including AVIM Therapy and Virtue SAB, both undergoing pivotal clinical trials.
Read more →OBIOOrchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
Orchestra BioMed Holdings, Inc. announced its participation in the Wells Fargo 21st Annual Healthcare Conference, where CEO David Hochman will present and hold one-on-one meetings with investors. The company is focused on high-impact biomedical technologies, including its AVIM Therapy and Virtue SAB, both of which are undergoing pivotal clinical trials. These products target significant health issues and have received FDA Breakthrough Device Designations.
Read more →OBIO▲ +12%on this news
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
Orchestra BioMed Holdings, Inc. has announced its inclusion in the Russell 3000 and Russell 2000 indexes following the 2026 reconstitution. This membership is significant as it enhances the company's visibility among investors and aligns it with a broad range of market capitalizations. The company is known for its innovative biomedical technologies, including therapies for hypertension and atherosclerotic artery disease.
Read more →OBIOOrchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Orchestra BioMed announced the grant of stock options to five new employees as part of its 2025 New Hire Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The company is focused on advancing its flagship product candidates, AVIM Therapy and Virtue SAB, which are in pivotal clinical trials and target significant market opportunities in hypertension and atherosclerotic artery disease.
Read more →OBIOOrchestra BioMed to Participate in the Jefferies Global Healthcare Conference
Orchestra BioMed Holdings, Inc. announced its participation in the Jefferies Global Healthcare Conference. CEO David Hochman will engage in a fireside chat and hold one-on-one meetings with investors. The event highlights the company's innovative therapies, including AVIM Therapy and Virtue SAB, both of which have received FDA Breakthrough Device Designations.
Read more →OBIOOrchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Orchestra BioMed reported its Q1 2026 financial results, highlighting advancements in its BACKBEAT Trial and AVIM Therapy. The company aims to complete enrollment by Q3 2026 and plans a late-breaking presentation at a major cardiology conference in Q2 2027. The FDA granted a second Breakthrough Device Designation for AVIM Therapy, enhancing its market potential. Despite a net loss increase, the company maintains a strong cash runway through Q4 2027.
Read more →OBIOOrchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
Orchestra BioMed aims to complete enrollment for the BACKBEAT Trial by Q3 2026, evaluating AVIM Therapy for hypertension in pacemaker patients. The company plans to present primary endpoint results at a major cardiology conference in Q2 2027. Medtronic will seek FDA approval for AVIM Therapy following successful data analysis.
Read more →OBIOOrchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Orchestra BioMed has received a $15 million investment from Ligand Pharmaceuticals, completing a scheduled tranche under a royalty-based financing agreement. This investment brings the total capital from Ligand to $40 million, aimed at supporting pivotal trials for its AVIM Therapy and Virtue SAB. The funding reflects confidence in the potential of these therapies to address significant unmet medical needs in cardiovascular health.
Read more →OBIOOrchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
Orchestra BioMed has received a $20 million payment from Medtronic as part of a strategic financing agreement. This funding will support the BACKBEAT Trial, which evaluates Atrioventricular Interval Modulation Therapy for patients with uncontrolled hypertension. The investment reflects Medtronic's commitment to advancing this innovative treatment, which has received FDA Breakthrough Device Designation.
Read more →OBIO▲ +5%on this news
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
Orchestra BioMed has received a second Breakthrough Device Designation from the FDA for its Atrioventricular Interval Modulation (AVIM) Therapy, targeting patients with uncontrolled hypertension. This designation covers a broad patient population and supports favorable reimbursement pathways. The therapy is being evaluated in the BACKBEAT Trial, conducted in collaboration with Medtronic, aiming to improve patient outcomes in hypertension management.
Read more →OBIOOrchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
Orchestra BioMed announced that it will present new clinical and mechanistic data on its AVIM Therapy at the HRS 2026 Annual Meeting. The data from the MODERATO II trial showcase significant reductions in office systolic blood pressure among patients. AVIM Therapy showed an immediate average reduction of 13.2 mmHg, with 97% of patients achieving significant blood pressure reductions. The company is also actively enrolling patients for the BACKBEAT Global Pivotal Trial to further evaluate AVIM Therapy's efficacy.
Read more →OBIOOrchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Orchestra BioMed reported a strong financial performance for 2025, with revenues soaring to $33.5 million, driven by strategic partnerships and agreements. The company is well-positioned for future growth with a cash position of $106.5 million and ongoing pivotal trials for its AVIM Therapy and Virtue SAB programs. CEO David Hochman highlighted the successful enrollment in these trials and the positive impact of recent transactions with Medtronic and Terumo.
Read more →OBIOOrchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
Orchestra BioMed announced presentations at THT and CRT 2026, showcasing their Atrioventricular Interval Modulation Therapy (AVIM Therapy) for hypertensive heart disease and heart failure. Presenters highlighted clinical data demonstrating significant reductions in systolic blood pressure and improvements in cardiac function. The therapy is positioned as a novel treatment option for patients with limited alternatives.
Read more →OBIOOrchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is set to participate in multiple upcoming institutional investor conferences. The company will engage in live fireside chats and one-on-one meetings at the TD Cowen 46th Annual Health Care Conference and Barclays 28th Annual Global Healthcare Conference. These events will allow Orchestra BioMed to connect with investors and enhance visibility within the industry through live webcasts.
Read more →About Orchestra BioMed Holdings, Inc.
Headquarters150 UNION SQUARE DRIVE, NEW HOPE, PA, 18938
BIOPHARMAWATCH ELITE PLUS
Trade the next OBIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime